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Abstract
Antipsychotic-induced dyslipidemia could increase the risk of cardiovascular diseases. This is a meta-analysis of
randomized double-blind placebo-controlled trials to examine the efficacy and safety of adjunctive metformin for
dyslipidemia induced by antipsychotics in schizophrenia. The standardized mean differences (SMDs) and risk ratios
(RRs) with their 95% confidence intervals (CIs) were calculated using the random-effects model with the RevMan 5.3
version software. The primary outcome was the change of serum lipid level. Twelve studies with 1215 schizophrenia
patients (592 in metformin group and 623 in placebo group) were included and analyzed. Adjunctive metformin was
significantly superior to placebo with regards to low density lipoprotein cholesterol (LDL-C) [SMD: −0.37 (95%CI:−0.69,
−0.05), P= 0.02; I2= 78%], total cholesterol [SMD: −0.47 (95%CI:−0.66, −0.29), P < 0.00001; I2= 49%], triglyceride
[SMD: −0.33 (95%CI:−0.45, −0.20), P < 0.00001; I2= 0%], and high density lipoprotein cholesterol [SMD: 0.29 (95%
CI:0.02, 0.57), P= 0.03; I2= 69%]. The superiority of metformin in improving LDL-C level disappeared in a sensitivity
analysis and 80% (8/10) of subgroup analyses. Metformin was significantly superior to placebo with regards to
decrease in body weight, body mass index, glycated hemoglobin A1c, fasting insulin, and homeostasis model
assessment-insulin resistance (P= 0.002–0.01), but not regarding changes in waist circumference, waist-to-hip rate,
leptin, fasting glucose, and blood pressure (P= 0.07–0.33). The rates of discontinuation due to any reason [RR: 0.97
(95%CI: 0.66, 1.43), P= 0.89; I2= 0%] was similar between the two groups. Adjunctive metformin could be useful to
improve total cholesterol and triglyceride levels, but it was not effective in improving LDL-C level in schizophrenia.
Introduction
Use of antipsychotics, particularly atypical anti-
psychotics, has been associated with a higher risk of
metabolic and cardiovascular adverse effects1–3 and even
premature death4,5, which could be significantly attrib-
uted to dyslipidemia6, particularly elevated low density
lipoprotein cholesterol (LDL-C)7–9.
Dyslipidemia, such as increased level of total choles-
terol, triglyceride, LDL-C and decreased level of high
density lipoprotein cholesterol (HDL-C), could occur in
around two-thirds of patients with schizophrenia10. Life-
style and dietary interventions has been found to be safe
and effective in treating dyslipidemia11,12. Several meta-
analyses have found that topiramate12, metformin13, and
rosuvastatin14 were also effective and safe in improving
dyslipidemia induced by antipsychotics in schizophrenia.
Metformin, a biguanide hypoglycemic agent, is widely
prescribed for type 2 diabetes1. Animal studies have found
metformin is effective in treating weight gain induced by
olanzapine15 and dyslipidemia induced by risperidone16.
Case reports and open-label studies also found that
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metformin could improve body weight17 and metabolic
syndrome17. However, the findings of randomized double-
blind placebo-controlled trials (RCTs)6,18–28 examining
the effects of adjunctive metformin for dyslipidemia
induced by antipsychotics have been mixed.
Some reviews and meta-analyses11,13,29–37 have exam-
ined the efficacy and safety of adjunctive metformin for
antipsychotics-related weight gain and metabolic
abnormalities in schizophrenia. However, the primary
outcome in most meta-analyses was weight gain, rather
than dyslipidemia, and some meta-analyses included
open-label studies, which deviate from the standardized
recommendations38. In addition, the findings of the pre-
vious meta-analyses12,13,33,35,37 on adjunctive metformin
for dyslipidemia, such as total cholesterol, HDL and LDL
cholesterol, have been inconsistent. Thus, we conducted
this meta-analysis of RCTs in English and Chinese lit-
erature to examine the efficacy and safety of adjunctive
metformin for dyslipidemia induced by antipsychotics in
schizophrenia.
Methods
Search strategy
Both international (PubMed, Cochrane Library, Psy-
cINFO, and EMBASE) and Chinese (Chinese Journal Net,
and WanFang) databases were independently searched to
obtain relevant published RCTs by three investigators
(WLJ, DBC, and FY) from their commencement dates to
October 22, 2018, using the search terms as follows:
(“metformin”[MeSH] OR metformin OR Dimethylbigua-
nidine OR Dimethylguanylguanidine OR Glucophage)
AND (“dyslipidemias”[MeSH] OR Dyslipidemias OR
Dyslipidemia OR Dyslipoproteinemias OR Dyslipopro-
teinemia OR metabolic OR lipid OR fats OR Hypolipi-
demic Agents OR cholesterol OR HDL OR LDL OR
lipoprotein OR triglyceride OR adiponectin OR ghrelin
OR leptin OR resistin OR chemerin OR omentin OR
apelin or adipocytokine OR adipokine) AND (“schizo-
phrenia”[Mesh] OR schizophrenic disorder OR disorder,
schizophrenic OR schizophrenic disorders OR schizo-
phrenia OR dementia praecox). The references of relevant
reviews11,13,29–37 were also searched manually to avoid
missing publications.
Inclusion criteria of the meta-analysis
The inclusion criteria of this meta-analysis were made
according to PICOS acronym. Participants: patients with
schizophrenia diagnosed according to international or
local diagnostic criteria, such as the China’s mental dis-
order classification and diagnosis standard, 3rd edition,
International Classification of Diseases, 10th edition or
Diagnostic and Statistical Manual of Mental Disorders,
4th edition. Intervention: adjunctive metformin with
treatment as usual (TAU). Comparison: TAU plus
placebo. Outcomes: the primary outcome was LDL-C
(mg/dL); the secondary outcomes were total cholesterol
(mg/dL), triglyceride (mg/dL), HDL-C (mg/dL), body
weight (kg), body mass index (BMI, kg/m2), waist cir-
cumference (cm), waist-to-hip rate, leptin (ug/L), glycated
hemoglobin A1c (HbA1c, %), fast insulin (mIU/L) and
homeostasis model assessment of insulin resistance
(HOMA-IR), fasting glucose (mmol/L), blood pressure
including diastolic and systolic blood pressure (mmHg),
adverse drug reactions (ADRs), and discontinuation due
to any reason. Study: following other meta-analyses39,40,
only published double-blind RCTs that examined the
efficacy and safety of metformin for dyslipidemia with
available data were included. Studies without data of
blood lipid were excluded41–43.
Data extraction
Three investigators (WLJ, DBC, and FY) independently
extracted relevant data of eligible studies, including study
characteristics (such as first author, publication year and
sample size), basic demographic and clinical data (such as
age, percentage of males, diagnostic criteria, illness
duration, antipsychotic and its doses) and outcomes
(efficacy, safety and tolerability of metformin). Dis-
crepancies in literature search and data extraction were
resolved through negotiation, or consultations with a
senior investigator (WZ). One study19 with 2 active
treatment arms compared two different doses of metfor-
min with placebo. The data of these three groups (2 active
treatment arms + 1 placebo group) were separately
extracted and analyzed in this meta-analysis. In order to
avoid inflating the total number of patients in the placebo
group, we assigned half of those in the placebo group to
each metformin arm.
Statistical analyses
The data analyses were performed by the RevMan,
version 5.3 according to the recommendations of the
Cochrane Collaboration44. The random-effects model was
used for all meta-analyzable outcomes45. The standar-
dized mean differences (SMDs) and their 95% confidence
intervals (CIs) were calculated for continuous outcomes.
The risk ratios (RRs) and their 95% CIs were calculated
for categorical outcomes. Significant heterogeneity was
defined by I2 of >50% or P value of <0.1 in Q-test.
In case of I2 ≥ 50% for LDL-C level, a sensitivity analysis
was conducted to detect the source of heterogeneity after
removing 1 outlying study (SMD ≤−0.87)18. Furthermore,
the following six subgroup analyses were conducted to
identify the sources of heterogeneity of the primary out-
come: (i) Chinese vs. non-Chinese studies; (ii) studies with
olanzapine vs. studies that did not use olanzapine as the
primary antipsychotic medication; (iii) trial duration
(weeks): ≥16 vs. <16; (iv) no sex predominance vs. male
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predominance (≥60%); (v) high quality (Jadad score ≥3) vs.
low quality (Jadad score <3); and (vi) age (years): ≥39.3 vs.
<39.3 (using the mean split of age). Sensitivity and sub-
group analyses were not performed for total cholesterol
and triglyceride levels, as the heterogeneity was small
(I2= 49% and 0%, respectively). Publication bias was
examined by visual funnel plots and Egger’s test46 using
comprehensive meta-analysis program version 2. All
meta-analytic primary and secondary outcomes were two
tailed, with alpha set at 0.05.
Assessment of study quality
The quality of included RCTs was independently
assessed by three investigators (WLJ, DBC, and FY) using
Jadad scale47,48 and the Cochrane Risk of bias49. The
overall evidence levels of all meta-analytic outcomes were
measured using the grading of recommendations,
assessment, development, and evaluation (GRADE)
system50,51.
Results
Computer search
A total of 454 hits (Fig. 1) were identified from the
databases (n= 451) and manual search (n= 3). Finally,
12 studies with 13 RCTs6,18–28 were included in this
meta-analysis. Of them, one study contained two
RCTs6.
Study characteristics
The 12 studies with 13 RCTs covered 1215 patients (592
in the metformin group (500–2550mg/day) and 623 in
the placebo group; Table 1). The mean age was 39.3
(range= 26.0–47.7) years and the mean illness duration in
11 studies with available data was 10.7 (range= 0.5–24.8)
years. The mean trial duration was 15.5 (range= 8–24)
weeks. Eight RCTs were conducted in China (n= 826),
three in Venezuela (n= 181), and one each in Iran
(n= 60) and the USA (n= 148).
Quality assessment of included study
Of the 13 RCTs, only 1 RCT22 was rated as high risk
with regards to the random sequence generation and
allocation concealment (Supplemental Fig. 1). Other bias
was rated as unclear in all RCTs. The Jadad total scores
ranged from 2 to 5; 11 RCTs were rated as high quality
(Jadad score ≥ 3). The quality of evidence for primary and
secondary outcomes using the GRADE approach ranged
from “low” (8.4%, 2/24), to “moderate” (45.8%, 11/24), and
“high” (45.8%, 11/24) (Supplemental Table 1).
Serum lipid
Adjunctive metformin was significantly superior to
placebo with regard to LDL-C level [SMD: −0.37 (95%CI:
−0.69, −0.05), P= 0.02; I2= 78%], total cholesterol level
[SMD: −0.47 (95%CI:−0.66, −0.29), P < 0.00001;
Individual hits 
in PubMed 
(n=34)
Individual hits 
in PsycINFO 
(n=22)
Individual hits in 
Cochrane 
Library (n=29)
Individual hits 
in Wanfang 
(n=86)
Individual hits in 
Chinese Journal 
Net (n=32)
Manual
search
(n=3)
Records after duplicates removed (n=358)
Records screened (n=358) Records excluded based on title and 
abstract (n=308)
Full-text articles assessed for 
eligibility (n=50)
Full-text articles excluded (n=38):
- Open label or single blind studies 
(n=20)
-Not randomised (n=1)
-Combined behavior intervention (n=1)
-Conference abstracts (n=5)
-No lipid data (n=5)
-No placebo control (n=2)
-Reviews (n=4)
Studies included in qualitative 
synthesis (n=12)
Studies included in quantitative 
synthesis (meta-analysis) (n=12 
studies with 13 RCTs) 
Individual hits 
in EMBASE 
(n=248)
Fig. 1 Flow chart of literature search and study selection. This figure described the route of studies inclusion.
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I2= 49%], triglyceride level [SMD: −0.33 (95%CI:−0.45,
−0.20), P < 0.00001; I2= 0%], and HDL-C level [SMD:
0.29 (95%CI:0.02, 0.57), P= 0.03; I2= 69%] (Fig. 2).
The significance with regard to LDL-C level disappeared
[SMD: −0.28 (95%CI:− 0.61, 0.05), P= 0.10; I2= 75%]
after 1 outlying (SMD ≤−0.87) study18 was removed.
Similarly, the significance disappeared in 8 of the 10 sub-
group analyses (Table 2).
Anthropometric variables
Metformin was significantly superior to placebo with
regards to decrease in body weight [SMD: −0.35 (95%CI:
−0.59, −0.11), P= 0.005; I2= 69%], BMI [SMD: −0.39
(95%CI: −0.66, −0.12), P= 0.005; I2= 76%], but not
regarding waist circumference [SMD: −0.15 (95%CI:
−0.45, 0.15), P= 0.33; I2= 71%], and waist-to-hip rate
[SMD: −0.46 (95%CI: −1.19, 0.27), P= 0.22; I2= 91%],
leptin [SMD: −1.09 (95%CI: −2.26, 0.07), P= 0.07; I2=
94%] (Table 3).
Carbohydrate metabolism
Metformin was significantly superior to placebo with
regards to HbA1c [SMD: −0.32 (95%CI:−0.52, −0.12),
P= 0.002; I2= 0%], fasting insulin [SMD: −0.73 (95%CI:
−1.22, −0.24), P= 0.003; I2= 87%] and HOMA-IR [SMD:
−0.89 (95%CI:−1.57, −0.21), P= 0.01; I2= 92%], but not
regarding fasting glucose [SMD: −0.31 (95%CI: −0.67,
0.04), P= 0.09; I2= 88%] (Table 3).
Blood pressure
No significant differences were found regarding diastolic
[SMD: −0.11 (95%CI: −0.31, 0.10), P= 0.30; I2= 0%] and
systolic blood pressure [SMD: −0.15 (95%CI: −0.35, 0.06),
P= 0.16; I2= 0%] between two groups (Table 3).
Adverse drug reactions and discontinuation rate
Compared with placebo, adjunctive metformin was
significantly associated with more frequent nausea/
vomiting (P= 0.02, 95%CI= 11–50). No significant group
differences were found in other ADRs (P= 0.14–0.98) and
discontinuation due to any reason [RR: 0.97 (95%CI: 0.66,
1.43), P= 0.89; I2= 0%] (Table 3).
Publication bias
The funnel plots of included studies were symmetrical
and Egger’s test did not detect publication bias for tri-
glyceride level (P= 0.50), body weight (P= 0.50), and
fasting glucose (P= 0.97). Publication bias of other meta-
analytic outcomes could not be examined due to small
numbers (n < 10) of RCTs52.
Discussion
This meta-analysis found that adjunctive metformin
was effective, safe, and generally well-tolerated in treating
total cholesterol and triglyceride levels with “high” evi-
dence level assessed by the GRADE approach within
schizophrenia patients for antipsychotic-induced dyslipi-
demia, which is consistent with the findings in studies
involving several other adjunctive medications, such as
rosuvastatin (total cholesterol level vs. triglyceride level:
SMD=−2.00 vs. −1.05)14. However, the significant
superiority of metformin over placebo in the improve-
ment of LDL-C level was driven by an outlying study18.
Similarly, metformin was not effective in improving LDL-
C level in 8 of the 10 subgroup analyses. This meta-
analysis found the significant superiority of adjunctive
metformin over placebo regarding LDL-C, total choles-
terol, triglyceride and HDL-C level with small effect
sizes53. Convincing evidence showed that findings with
small effect size could be also reliable in clinical practice.
For instance, a recent network meta-analysis that com-
pared the efficacy and acceptability of 21 antidepressant
drugs for major depressive disorder found that all anti-
depressants were more efficacious than placebo in
improving depressive symptoms, but only small effect
sizes were achieved54.
The mechanism of metformin underlying the treatment
of antipsychotic-inducted dyslipidemia is still not clear.
One possible explanation may be related to the role of
metformin in improving insulin resistance6,19,33,35 which is
a risk factor of dyslipidemia55 and could decrease lipo-
protein synthesis56. In addition, the therapeutic effects of
metformin in treating antipsychotic-inducted dyslipidemia
may be associated with its role in the neuronal reduction of
endogenous glucose production, increasing glucagon-like
peptide-1 production, decreasing bile acid concentration in
enterocytes, and modulating the gut microbiota56.
In this meta-analysis, adjunctive metformin showed
significant benefits for reducing body weight and BMI,
which is consistent with the findings of other meta-
analysis13,57. For example, a recent meta-analysis found
that a combination of metformin and lifestyle modifica-
tion could significantly reduce body weight and BMI
compared with placebo, lifestyle group or metformin
alone11. Adjunctive metformin for antipsychotic-induced
dyslipidemia were generally safe and well-tolerated. In this
meta-analysis, seven studies reported more frequent
nausea/vomiting in adjunctive metformin compared with
placebo. A meta-analysis of use of adjunctive metformin
for antipsychotic-induced weight gain also found that
metformin could lead to more frequent reports of nausea/
vomiting than placebo13.
Some studies found that long-term use of metformin
was associated with decreased vitamin B12 levels, and even
biochemical B12 deficiency
2,58. Thus, blood lactate con-
centration, serum B12 levels and folate levels should be
regularly screened for patients with schizophrenia when
they received metformin treatment2.
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Fig. 2 Adjunctive metformin for antipsychotic-induced dyslipidemia: forest plot for serum lipid. Adjunctive metformin was significantly
superior to placebo with regard to LDL-C level, total cholesterol level, triglyceride level, and HDL-C level. HDL-C high density lipoprotein cholesterol,
LDL-C low density lipoprotein cholesterol.
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Several meta-analyses11,13,29–37 had examined
antipsychotic-induced body weight and metabolic
abnormalities in schizophrenia, however, only a small
number of them with comparatively smaller sample size
meta-analyzed dyslipidemia as a secondary outcome33,35,37.
This meta-analysis only included double-blind RCTs
examining adjunctive metformin for dyslipidemia in schi-
zophrenia, together with a large sample size increase the
robustness and reliability of meta-analytic findings.
Several limitations should be noted. First, the significant
heterogeneity for primary outcome remained, even in
some subgroup analyses. For this reason, we tried to
compensate for study heterogeneity using the random-
effects model and conducting subgroup analyses. Second,
although unpublished studies were not searched, no
publication bias was found for triglyceride level, body
weight, and fasting glucose in this meta-analysis. Third,
the dose-response effect of metformin as an adjunctive
treatment for dyslipidemia was not examined since the
doses of metformin varied across included RCTs
(500–2550mg/day). Fourth, the significant superiority of
metformin over placebo in improving LDL-C level was
found in RCTs lasting more than 16 weeks, but not in
those less than 16 weeks. Furthermore, the long-term
effect (beyond 24 weeks) of adjunctive metformin for
antipsychotic-induced dyslipidemia was not examined.
In conclusion, adjunctive metformin could improve
total cholesterol and triglyceride levels but its therapeutic
effects on LDL-C level was less certain in this meta-
analysis. The prolonged effect of active agents such as
metformin to treat dyslipidemia induced by antipsychotics
in schizophrenia needs to be further examined.
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Table 2 Subgroup analyses of metformin for LDL-C level.
Variables Active arms
(subjects)
SMDs (95%CI) I2 (%) P
1. Chinese 3 (480) −0.57 (−1.13, −0.00) 89 0.05
Non-Chinese 4 (292) −0.16 (−0.39, 0.07) 0 0.16
2. Antipsychotic
class: olanzapine
3 (229) −0.41 (−1.06, 0.23) 81 0.21
Other than
olanzapine
4 (543) −0.33 (−0.75, 0.08) 81 0.11
3. Trial duration
(weeks): ≥16
5 (663) −0.44 (−0.82, −0.06) 82 0.02
<16 2 (109) −0.13 (−0.70, 0.44) 51 0.66
4. Jadad scorea ≥ 3 6 (602) −0.44 (−0.78, −0.10) 74 0.01
Jadad score <3 1 (170) −0.01 (−0.31, 0.29) N/A 0.93
5. Age (years)a:
≥39.3
5 (412) −0.34 (−0.70, 0.02) 67 0.07
<39.3 2 (360) −0.42 (−1.23, 0.38) 93 0.30
Bold P values: P < 0.05.
CI confidence interval, N/A not applicable, LDL-C low density lipoprotein
cholesterol, SMDs standard mean differences.
aAnalyzed using a mean splitting method.
Table 3 Adjunctive metformin for antipsychotic-induced
dyslipidemia: secondary outcomes.
Variables Active arms
(subjects)
SMDs/RRs (95%CI) I2 (%) P
Clinical features
Body weight (kg) 11 (1004) −0.35 (−0.59, −0.11) 69 0.005
BMI (kg/m2) 12 (1016) −0.39 (−0.66, −0.12) 76 0.005
Waist
circumference (cm)
9 (681) −0.15 (−0.45, 0.15) 71 0.33
WHR 3 (346) −0.46 (−1.19, 0.27) 91 0.22
Leptin (ug/L) 3 (238) −1.09 (−2.26, 0.07) 94 0.07
Fasting glucose
(mmol/L)
13 (1161) −0.31 (−0.67, 0.04) 88 0.09
HbA1c (%) 4 (384) −0.32 (−0.52, −0.12) 0 0.002
Fast insulin (mIU/L) 5 (615) −0.73 (−1.22, −0.24) 87 0.003
HOMA-IR 6 (501) −0.89 (−1.57, −0.21) 92 0.01
Diastolic blood
pressure (mmHg)
5 (371) −0.11 (−0.31, 0.10) 0 0.30
Systolic blood
pressure (mmHg)
5 (371) −0.15 (−0.35, 0.06) 0 0.16
Discontinuation rate
Discontinuation due
to any reason
9 (806) 0.97 (0.66, 1.43) 0 0.89
ADRs
Nausea/vomiting 7 (765) 1.51 (1.05, 2.16) 0 0.02
Dizziness 2 (315) 1.99 (0.56, 7.06) 0 0.29
Dry mouth 4 (596) 1.76 (0.82, 3.76) 0 0.14
Hypersomnia 2 (371) 0.45 (0.02, 11.25) 77 0.63
Tachycardia 2 (315) 0.86 (0.26, 2.83) 16 0.80
Headache 2 (316) 1.02 (0.17, 6.05) 44 0.98
Constipation 3 (395) 1.23 (0.52, 2.88) 10 0.64
Diarrhea 5 (394) 1.43 (0.86, 2.41) 19 0.17
Bold P values: P < 0.05.
ADRs adverse drug reactions, BMI body mass index, CI confidence interval, HbA1c
glycated hemoglobin A1c, HOMA-IR homeostasis model assessment-insulin
resistance, RRs risk ratios, SMDs standardized mean differences, WHR waist-to-
hip ratio.
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